Neuronata-R retains conditional approval in South Korea
South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 20, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea will keep their access to Neuronata-R® (lenzumestrocel) — a stem...
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion. Strong transaction support, with a unanimous recommendation from PolyPeptide's Board members (acting through its...
NYSE Content Update: AdvanCell Raises $315 Million to Fight Prostate Cancer
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 17, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Voyager Awarded $298 Million NASA...
DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5...
Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow
GOTHENBURG, Sweden, July 17, 2026 /PRNewswire/ -- "We delivered a strong quarter both financially and operationally with several important key achievements," says Mattias Perjos, President and CEO of Getinge. Sales in Acute Care Therapies increased in most product categories, and the positive trend in consumables for life-supporting ECLS therapy was maintained. Surgical Workflows continued to display good momentum....
Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform
Targets Japan and Singapore as Part of Broader Asia Expansion TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstream regenerative medicine materials, process-development capabilities and quality-testing services, highlighting the build-out and service capacity of its Zhubei...
HEALEY ALS Platform Trial Regimen I enrolment completed – Topline results for NUZ-001 accelerated to Q2 CY2027
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027 Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program Reflects strong recruitment and...
VARON Shares Summer Respiratory Wellness Tips and Introduces Seasonal Savings on Oxygen Solutions
LOS ANGELES, July 17, 2026 /PRNewswire/ -- Summer is a season for outdoor activities, family gatherings and travel, but rising temperatures, humidity and changing air conditions can create challenges for individuals focused on respiratory wellness. VARON is sharing practical tips to help oxygen users stay prepared, comfortable and confident while enjoying the activities that matter most. For people who...
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix Pharmaceuticals (ASX: TLX,...
HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep-Disordered Breathing Analysis
- FDA 510(k) Clearance (K253390) Validates AI-Based Classification of OSA, CSA, and MSA- Subtype-Specific Respiratory Event Analysis Improves Diagnostic Precision and Supports Next-Generation Digital Biomarker Development- Advanced AI Analysis Using Multi-Channel Physiological Signals, with Additional FDA 510(k) Clearances Planned for Future Releases BOSTON, July 16, 2026 /PRNewswire/ -- HoneyNaps, an AI-based sleep medicine company, today announced that SOMNUM...
